Anti-VEGF Treatment Linked to Glaucoma Risk in 2026 Study
Researchers found a significantly higher incidence of eye pressure issues in diabetic patients receiving anti-VEGF therapy.
Updated on Oct. 12, 2026 in Diabetes
Live Poll
Do you trust that your doctor sufficiently monitors the long-term side effects of your prescribed treatments?
A retrospective study presented in 2026 revealed that diabetic macular edema patients treated with anti-VEGF agents faced a higher risk of developing glaucoma or ocular hypertension over five years. The findings highlight a potential long-term ocular complication associated with this common therapeutic intervention.
Why it matters
Understanding the potential side effects of anti-VEGF treatments is essential for managing diabetic macular edema, as clinicians weigh vision-saving benefits against the risk of secondary eye conditions. This data provides critical context for patient monitoring and long-term care planning.
The study utilized the TriNetX US Collaborative network to track over 40,000 patients, identifying a hazard ratio of 2.8 for glaucoma or ocular hypertension. Treated patients showed a 10.46% incidence rate over five years compared to 4.09% in the control group.
The players
EURETINA
This is a professional organization dedicated to the advancement of European vitreoretinal and macula specialists.
TriNetX
This is a global research network that provides access to longitudinal clinical data for health care organizations and life sciences companies.
The details
Researchers performed a retrospective analysis of more than 40,000 patients, using propensity score matching to compare those receiving anti-VEGF treatment against a control group with diabetic macular edema. Participants with prior open-angle glaucoma, ocular hypertension, or long-term systemic corticosteroid use were excluded from the analysis.
Timeline
The EURETINA 2026 conference took place in 2026.
Patient risk was observed over a duration of 5 years.
The Big Picture
The findings presented at the EURETINA 2026 conference represent a significant update in how clinicians interpret the long-term safety profile of ocular therapies. This analysis follows a pattern set by recent comparative effectiveness studies in ophthalmology that aim to refine care standards for chronic eye conditions.
Patients undergoing anti-VEGF therapy for diabetic macular edema may benefit from discussing long-term monitoring for ocular hypertension with their specialists. This study suggests that regular eye pressure checks are vital to identifying and addressing potential secondary complications early.
The takeaway
Patients receiving anti-VEGF treatment should prioritize regular screenings to detect any signs of glaucoma or ocular hypertension. Open communication with ophthalmologists regarding these risks can ensure that therapeutic plans remain safe and effective over the long term.
Further reading
Learn more about the latest clinical developments in Diabetes.
Source note: This article includes information reported by Medscape.
Live Poll
Do you trust that your doctor sufficiently monitors the long-term side effects of your prescribed treatments?
